Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG40023)
Regulator Name | Circ_0067934 (circRNA) | ||||
---|---|---|---|---|---|
Synonyms |
Circ_0067934
Click to Show/Hide
|
||||
Gene Name | Circ_0067934 | ||||
Regulator Type | circRNA |
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
Circ_0067934
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Cystine/glutamate transporter (SLC7A11) [Driver; Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Thyroid cancer | ICD-11: 2D10 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell proliferation | |||||
In Vitro Model |
FTC-133 cells | Thyroid gland follicular carcinoma | Homo sapiens | CVCL_1219 | |
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
BALB/c nude mice (18-20 g, 4-week-old, male) (n = 6) were purchased and applied for the tumor growth analysis of FTC133 cellsin vivo. About 1 x 106 FTC133 cells were transfected with control shRNA or circ_0067934 shRNA and were subcutaneously injected into the left fat pad of mice. After 5 days of injection, we measured tumor growth every 5 days. We sacrificed the mice after 30 days of injection. The tumor volume was calculated by (length x width2)/2. And the tumor weight was calculated at day 30.
Click to Show/Hide
|
||||
Response regulation | Circ_0067934 upregulated the expression of the ferroptosis-negative regulator SLC7A11 by sponging and inhibiting miR-545-3p in thyroid cancer cells. The overexpression of SLC7A11 or the inhibitor of miR-545-3p reversed circ_0067934 silencing-regulated thyroid cancer cell proliferation. | ||||
Thyroid cancer [ICD-11: 2D10]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Circ_0067934 (circRNA) | circRNA | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell proliferation | |||||
In Vitro Model |
FTC-133 cells | Thyroid gland follicular carcinoma | Homo sapiens | CVCL_1219 | |
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
BALB/c nude mice (18-20 g, 4-week-old, male) (n = 6) were purchased and applied for the tumor growth analysis of FTC133 cellsin vivo. About 1 x 106 FTC133 cells were transfected with control shRNA or circ_0067934 shRNA and were subcutaneously injected into the left fat pad of mice. After 5 days of injection, we measured tumor growth every 5 days. We sacrificed the mice after 30 days of injection. The tumor volume was calculated by (length x width2)/2. And the tumor weight was calculated at day 30.
Click to Show/Hide
|
||||
Response regulation | Circ_0067934 upregulated the expression of the ferroptosis-negative regulator SLC7A11 by sponging and inhibiting miR-545-3p in thyroid cancer cells. The overexpression of SLC7A11 or the inhibitor of miR-545-3p reversed circ_0067934 silencing-regulated thyroid cancer cell proliferation. | ||||